Many of the early studies with insulin–glucose/dextrose treatment (IDT) were performed in patients with end-stage kidney disease who were dialysis dependent or had significant chronic kidney disease (CKD) [2,3]. The gene discussed is INS; the disease is chronic kidney disease.